GBT Bucks Gene Therapy Trend With Sanofi Sickle Cell Deal
Pact Could Be Worth $353m
Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.
You may also be interested in...
The jury is still out on the case of MDS and some remaining questions regarding the AML case may still hinder commercial uptake.
The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.”
With more data reported at ASH, Vertex and CRISPR Therapeutics added heft to the notion that functional cures are on the horizon for the inherited blood disorders sickle cell disease and beta-thalassemia. Attention is now turning to Bluebird’s marketing strategy after a filing delay.